Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Mar 12;330(7491):568.
doi: 10.1136/bmj.38356.641134.8F. Epub 2005 Jan 31.

Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding

Grigoris I Leontiadis  1 , Virender K Sharma, Colin W Howden
Affiliations
Review

Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding

Grigoris I Leontiadis et al. BMJ. .

Abstract

Objectives: To review randomised controlled trials of treatment with a proton pump inhibitor in patients with ulcer bleeding and determine the impact on mortality, rebleeding, and surgical intervention.

Design: Systematic review and meta-analysis.

Data sources: Cochrane Collaboration's trials register, Medline, and Embase, handsearched abstracts, and pharmaceutical companies.

Review methods: Included randomised controlled trials compared proton pump inhibitor with placebo or H2 receptor antagonist in endoscopically proved bleeding ulcer and reported at least one of mortality, rebleeding, or surgical intervention. Trials were graded for methodological quality. Two assessors independently reviewed each trial, and disagreements were resolved by consensus.

Results: We included 21 randomised controlled trials comprising 2915 patients. Proton pump inhibitor treatment had no significant effect on mortality (odds ratio 1.11, 95% confidence interval 0.79 to 1.57; number needed to treat (NNT) incalculable) but reduced rebleeding (0.46, 0.33 to 0.64; NNT 12) and surgery (0.59, 0.46 to 0.76; NNT 20). Results were similar when the meta-analysis was restricted to the 10 trials with the highest methodological quality: 0.96, 0.46 to 2.01, for mortality; 0.41, 0.25 to 0.68, NNT 10, for rebleeding; 0.62, 0.46 to 0.83, NNT 25, for surgery.

Conclusions: Treatment with a proton pump inhibitor reduces the risk of rebleeding and the requirement for surgery after ulcer bleeding but has no benefit on overall mortality.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Funnel plots of included trials for mortality, rebleeding, and surgical intervention rates
Fig 2
Fig 2
Odds ratios for individual trials and pooled data for mortality, according to route of administration of proton pump inhibitor (PPI)
Fig 3
Fig 3
Odds ratios for individual trials and pooled data for rebleeding, according to route of administration of proton pump inhibitor (PPI)
Fig 4
Fig 4
Odds ratios for individual trials and pooled data for rates of surgical intervention, according to route of administration of proton pump inhibitor (PPI)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Agency for Healthcare Research and Quality. HCUP nationwide inpatient sample. Rock-ville, MD: Agency for Healthcare Research and Quality, 1997.
    1. Van Leerdam ME, Vreeburg EM, Rauws EAJ, Geraedts AAM, Tijssen JGP, Reitsma JB, et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol 2003;98: 1494-9. - PubMed
    1. Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994;331: 717-27. - PubMed
    1. Jensen DM, Kovacs TOG, Jutabha R, Machicado GA, Gralnek I, Savides TJ, et al. Randomized trial of medical or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology 2002;123: 407-13. - PubMed
    1. Laine L. Management of ulcers with adherent clots. Gastroenterology 2002;123: 632-6. - PubMed